compound,therapeutic_area,milestone_type,planned_date,status,days_variance
Etrolizib,Immunology,NDA Submission,2025-01-31,Delayed,89
Pirtobrutinib,Oncology,Primary Completion,2025-09-30,At Risk,55
Axaflutide,Immunology,NDA Submission,2025-03-31,At Risk,42
Foravumab,Oncology,Phase II Complete,2024-10-31,At Risk,30
